deltatrials
Completed PHASE3 INTERVENTIONAL 1-arm NCT03406507

A Study of Ravulizumab (ALXN1210) in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria

A Phase 3, Open-Label Study of ALXN1210 in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Sponsor: Alexion Pharmaceuticals, Inc.

Conditions Paroxysmal Nocturnal Hemoglobinuria
Interventions Ravulizumab
Updated 23 times since 2018 Last updated: Feb 23, 2023 Started: Feb 22, 2018 Primary completion: Mar 25, 2020 Completion: Aug 25, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Paroxysmal Nocturnal Hemoglobinuria, this trial is completed. The trial is conducted by Alexion Pharmaceuticals, Inc. and has accumulated 23 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Feb 2018 – ~Apr 2018 · 59 days · monthly snapshot~Apr 2018 – ~May 2018 · 30 days · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Sep 2018 · 2 months · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Feb 2019 · 4 months · monthly snapshot~Feb 2019 – ~Apr 2019 · 59 days · monthly snapshot~Apr 2019 – ~May 2019 · 30 days · monthly snapshot~May 2019 – ~Sep 2019 · 4 months · monthly snapshot~Sep 2019 – ~Nov 2019 · 2 months · monthly snapshot~Nov 2019 – ~Aug 2020 · 9 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Jun 2022 · 17 months · monthly snapshot~Jun 2022 – ~Sep 2022 · 3 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Jan 2023 · 2 months · monthly snapshot~Jan 2023 – ~Apr 2023 · 3 months · monthly snapshot~Apr 2023 – ~Dec 2023 · 8 months · monthly snapshot~Dec 2023 – ~Jul 2024 · 7 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

23 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Dec 2023 — Jul 2024 [monthly]

    Completed PHASE3

  5. Apr 2023 — Dec 2023 [monthly]

    Completed PHASE3

▶ Show 18 earlier versions

  1. Jan 2023 — Apr 2023 [monthly]

    Completed PHASE3

  2. Nov 2022 — Jan 2023 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  3. Sep 2022 — Nov 2022 [monthly]

    Active Not Recruiting PHASE3

  4. Jun 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  5. Jan 2021 — Jun 2022 [monthly]

    Recruiting PHASE3

  6. Aug 2020 — Jan 2021 [monthly]

    Recruiting PHASE3

  7. Nov 2019 — Aug 2020 [monthly]

    Recruiting PHASE3

  8. Sep 2019 — Nov 2019 [monthly]

    Recruiting PHASE3

  9. May 2019 — Sep 2019 [monthly]

    Recruiting PHASE3

  10. Apr 2019 — May 2019 [monthly]

    Recruiting PHASE3

  11. Feb 2019 — Apr 2019 [monthly]

    Recruiting PHASE3

  12. Oct 2018 — Feb 2019 [monthly]

    Recruiting PHASE3

  13. Sep 2018 — Oct 2018 [monthly]

    Recruiting PHASE3

  14. Jul 2018 — Sep 2018 [monthly]

    Recruiting PHASE3

  15. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE3

  16. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE3

  17. Apr 2018 — May 2018 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  18. Feb 2018 — Apr 2018 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Alexion Pharmaceuticals, Inc.
Data source: Alexion Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations